Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 1.00 |
| ▸ | CNR1 | P21554 | 13/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462270 | 1.00 | CNR2 (1.00) | CNR2CNR1HDAC1HDAC6 | |
| SCHEMBL17297546 | 0.90 | CNR2 (0.82) | CNR2CNR1HDAC1HDAC6 | |
| SCHEMBL17309664 | 0.88 | CNR2 (0.83) | CNR2CNR1HDAC1HDAC6 | |
| SCHEMBL28432461 | 0.86 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL28442777 | 0.84 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL28435122 | 0.84 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL17308094 | 0.84 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL30172457 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29398086 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3456194 | 0.82 | CNR2 (0.69) | CNR2CNR1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-10591497-B2 | Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family | RANDOX LABORATORIES LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-10591497-B2 | Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family | RANDOX LABORATORIES LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20150346227-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | NORTHERN BANK LIMITED (IE) | 2015-12-03 | — | — | US | disclosed |
| US-20150346227-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | NORTHERN BANK LIMITED (IE) | 2015-12-03 | — | — | US | disclosed |
| EP-2950103-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE 3-ADAMANTANYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | Randox Laboratories Ltd. (GB) | 2015-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | CNR2 1/4885CNR1 2/4885HDAC1 1337/4885 |
| US-20150346227-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | CNR2, CNR1, IDO1 | CNR2 1/4885CNR1 2/4885HDAC1 2347/4885 |
| US-10591497-B2 | Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family | CNR2, CNR1, IDO1 | CNR2 1/4885CNR1 2/4885HDAC1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.